Savara to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 11th
AUSTIN, TX -- (Marketwired) -- 09/05/17 --
Savara Inc.
(NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday September 11, 2017 at 10:00 a.m. Eastern Time in Kennedy I at the Lotte New York Palace Hotel in New York.
Interested parties can access a live audio webcast of the presentation on the Savara web site at www.savarapharma.com. An archived presentation will be available on the web site for 30 days.
About Savara
Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara's pipeline comprises Molgradex, a Phase 3 stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF for PAP, AeroVanc, an inhaled vancomycin for MRSA infection in Cystic Fibrosis in preparation for Phase 3, and Aironite, an inhaled sodium nitrite for HFpEF in Phase 2 development. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)
Contacts:
Savara Inc.
Ioana C. Hone
ir@savarapharma.com
(512) 961-1891
The Trout Group
Kelly Mueller
kmueller@troutgroup.com
(646) 378-2965
Source: Savara Inc.
